
Brain Tumor
On this page
Get care
Why choose UCSF Health for brain tumor treatment?
UCSF Health is home to nationally and internationally renowned brain tumor experts. We have one of the largest and most comprehensive brain tumor programs in the country and treat more patients each year than any other institution. Our physicians and researchers are at the forefront of new therapies and have developed treatments that help people with brain tumors live longer, healthier lives.
We treat all types and stages of benign (noncancerous) and malignant (cancerous) brain and spinal tumors. We routinely see the most complex and aggressive diseases, including:
Gliomas
Meningiomas
Metastatic brain tumors
Nerve and spine tumors
Neurofibromatosis type 1 (NF1)-related tumors
Pituitary tumors
Skull base tumors
Why choose UCSF Health for brain tumor treatment?
UCSF Health is home to nationally and internationally renowned brain tumor experts. We have one of the largest and most comprehensive brain tumor programs in the country and treat more patients each year than any other institution. Our physicians and researchers are at the forefront of new therapies and have developed treatments that help people with brain tumors live longer, healthier lives.
We treat all types and stages of benign (noncancerous) and malignant (cancerous) brain and spinal tumors. We routinely see the most complex and aggressive diseases, including:
Gliomas
Meningiomas
Metastatic brain tumors
Nerve and spine tumors
Neurofibromatosis type 1 (NF1)-related tumors
Pituitary tumors
Skull base tumors
Get care
World-class team
Our neurosurgeons, neuro-oncologists and radiation oncologists are leaders in their fields and have in-depth expertise in specific tumor types.Personalized medicine
We offer new treatments, such as targeted therapy and immunotherapy, tailored to the specific type of brain tumor you have.Pioneering research
We have more than 30 laboratories dedicated to brain tumor research and one of the largest clinical trial programs in the country.Advanced techniques
State-of-the-art brain mapping, stereotactic radiosurgery and focused ultrasound are just a few of our leading-edge brain tumor treatments.Comprehensive support
We offer support groups, as well as dedicated caregiver and survivorship programs, to help patients and families cope and heal.National recognition
We're consistently ranked among the nation's top hospitals in neurology, neurosurgery and cancer care by U.S. News & World Report .
Advanced brain tumor care
From diagnosis through treatment and beyond, you'll find a compassionate team and a care plan tailored to your needs. We translate leading-edge research into more effective patient care to ensure that your best outcome starts at UCSF Health.
Brain tumor diagnosis
Our diagnostic team includes neuropathologists and neuroradiologists who specialize in brain diseases. We use the latest imaging technologies to locate and diagnose brain tumors as quickly as possible, which means you can start treatment faster. We're also leading the development of AI-powered tools that can lead to more precise diagnoses and tumor removal.
Our researchers developed a new molecular profiling technique called the UCSF500 Cancer Gene Panel. This test identifies genetic changes (mutations) in the DNA of cancer cells. It can help us determine which treatments are most likely to be effective, especially for people with advanced cancer that hasn't responded to standard treatment.
Surgery for brain tumors
Our surgeons draw on a variety of techniques to successfully remove brain and spine tumors, even in cases previously considered inoperable. We use the most advanced technology to operate with exceptional accuracy and minimize effects on vital brain functions.
Our brain surgery capabilities include:
-
Awake brain mapping. We use imaging guidance and mild electrical stimulation to identify and protect areas of the brain that control speech, sensation and muscle movement during surgery. Many brain mapping techniques were pioneered at UCSF Health.
-
Endoscopic brain surgery. We can often remove tumors of the skull base, paranasal sinuses and pituitary glands entirely through the nasal cavity and sinuses, so you don't need a craniotomy or incisions in your face. UCSF Health is one of the country's leading programs for minimally invasive brain surgery.
-
Fluorescence-guided surgery. We use a compound called 5-ALA that makes difficult-to-see glioma cells light up during surgery. This technique allows surgeons to remove tumors more completely, potentially improving survival rates.
-
Laser interstitial thermal therapy (LITT). Also called MRI-guided laser ablation, LITT is a minimally invasive procedure that uses heat to destroy tumors. UCSF Health was the first in Northern California to offer LITT for certain types of brain tumors.
-
Supratotal resection. Our researchers found that removing a brain tumor along with some surrounding tissue — which often contains cancer cells that aren't visible on imaging scans — could improve outcomes. We use this approach to treat certain types of gliomas.
Radiation therapy for brain tumors
Our radiation oncologists carefully plan the dose, duration and timing of radiation therapy to customize your treatment. We use advanced imaging technology and the latest radiation delivery systems to target tumors while sparing healthy tissue.
UCSF Health is a leader in stereotactic radiosurgery. This noninvasive treatment delivers a powerful, precise dose of radiation to brain tumors with surgical precision. We offer two leading-edge stereotactic radiosurgery systems: Gamma Knife and CyberKnife.
Medication and targeted therapy for brain tumors
We may use chemotherapy or targeted therapy in combination with surgery or radiation therapy to treat brain tumors. Targeted therapies are drugs that target specific molecules in cancer cells to stop them from growing and dividing.
UCSF Health uses advanced molecular tests to determine who may benefit from targeted therapies. These include the UCSF500 Cancer Gene Panel and DNA methylation profiling, which analyzes the unique DNA "fingerprint" of cancer cells. Our researchers are also investigating the potential uses for immunotherapy, such as CAR T-cell therapy, to treat brain tumors.
Locations
Providers

Manish Aghi, MD, PhD
Brain and Tumor Neurosurgery • Neurosurgery
Nicholas A. Butowski, MD
Neuro-Oncology
Edward F. Chang, MD
Neurosurgery • Epilepsy Surgery
Susan M. Chang, MD
Neuro-Oncology
Excellence in patient care

Best in California and No. 7 in the nation for cancer care

Best in the West and No. 2 in the nation for neurology & neurosurgery
#1
in the U.S. for number of brain tumor patients treated
Related conditions & treatments
Conditions
- Benign Neoplasm of Brain
- Brain and Spine Tumors
- Brain Metastases
- Brain Neoplasms
- Central Nervous System Malignancy
- Spinal Cord Tumors
Treatments
- Awake Brain Tumor Surgery
- Biological Targeted Therapy
- Brain Surgery
- Brain Function Mapping
- Cancer Chemotherapy
- Cancer Immunotherapy
- Chimeric Antigen Receptor T-Cell Therapy
- CyberKnife
- Endoscopic Neurosurgery
Clinical trials
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaOpens in a new window
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or radiation therapy for MGMT unmethylated patients.A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaOpens in a new window
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.RMC-5552 Monotherapy in Adult Subjects With Recurrent GlioblastomaOpens in a new window
This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the formation of a specific group of proteins called mTOR. This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care TreatmentOpens in a new window
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence.Hyperpolarized Imaging in Diagnosing Participants With GliomaOpens in a new window
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesOpens in a new window
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade GliomaOpens in a new window
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T CellsOpens in a new window
This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distr...Opens in a new window
Incident rate of moderate or severe procedure and/or device related adverse eventsHyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant GliomaOpens in a new window
This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.
Accreditations & memberships

National Cancer Institute
The National Cancer Institute has designated UCSF Health a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
Commission on Cancer
UCSF Health's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
National Comprehensive Cancer Network
UCSF is a member of the National Comprehensive Cancer Network, an alliance of the world's top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Research initiatives
UCSF Brain Tumor Center Clinical TrialsOpens in a new window
The UCSF Brain Tumor Center is home to many laboratories dedicated to improving the understanding and treatment of brain cancer. The labs explore aspects of brain tumor risk, biology, diagnosis and treatment.UCSF Helen Diller Family Comprehensive Cancer Center ResearchOpens in a new window
UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.
Patient education

Brain Tumor Patient and Family Resource Guide
Coping with a brain tumor can be challenging. Get resources to help you navigate the physical, emotional and financial effects of the disease.
A day in the life of a neurosurgeon













